Lioton

Heparin Sodium, the active ingredient in Lioton, is an Anticoagulant presented as an unknown/unknown for Cutaneous use. It helps prevent abnormal clot formation in patients at risk of thrombosis and can be applied topically to support local anticoagulant effect. GNH USA supplies Lioton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lioton, containing Heparin Sodium, acts on the coagulation cascade to prevent and treat thromboembolic conditions. - Deep vein thrombosis: helps prevent clot extension and recurrence. - Pulmonary embolism: supports anticoagulation to reduce clot burden. - Superficial thrombophlebitis: applied topically to limit local clot formation.

Adverse reactions may occur with Lioton use.

Common Side Effects: - Injection site irritation: redness or mild pain at the application site. - Skin erythema: localized redness where the product is applied. - Minor bruising: increased tendency for small bruises at or near the site.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): sudden drop in platelet count that can lead to paradoxical clotting. - Bleeding complications: unexpected or excessive bleeding from any site. - Allergic reaction: hives, swelling, or anaphylaxis in susceptible individuals.

Before using Lioton, consider the following safety measures. - Renal impairment: monitor coagulation parameters closely. - History of bleeding disorders: assess risk before initiating therapy. - Concurrent anticoagulants: avoid additive bleeding risk. - Pregnancy: use only if clearly needed after risk‑benefit evaluation. - Surgery or invasive procedures: discontinue prior to the procedure as advised. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Heparin Sodium can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Warfarin: additive anticoagulant effect increasing bleeding risk. - Direct oral anticoagulants (e.g., apixaban, rivaroxaban): combined therapy may cause severe hemorrhage. - Thrombolytic agents (e.g., alteplase): heightened risk of major bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding tendencies. - Heparin flush solutions: avoid duplication of heparin exposure.